Hero Banner. LEQVIO® (inclisiran) logo.
Hero Banner. LEQVIO® (inclisiran) logo.

Prescribing information

All images are of fictional patients and healthcare practitioners

LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or

  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated

 The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1

For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.
 

LEQVIO® resources

Explore our growing repository of resources designed to provide useful information on LEQVIO® and other relevant topics for healthcare professionals treating eligible patients with ASCVD.

LEQVIO® dosing and administration video

For guidance and support on dosing and administration of LEQVIO® in eligible patients.

LEQVIO® mechanism of action video

Watch to see how LEQVIO® works to treat ASCVD in eligible patients.

Preview image. LEQVIO® Dosing and Administration Guide thumbnail.

LEQVIO® dosing and administration guide

For guidance and support on dosing and administration of LEQVIO® in eligible patients.

PDF
Download
Thumbnail image of the LEQVIO ORION-8 fact sheet.

LEQVIO® ORION-8 fact sheet

Clinical factsheet of the ORION-8 study. The study was designed to assess the long-term efficacy, safety and tolerability of LEQVIO in patients who entered an open-label extension (ORION-8) after completing either ORION-3, ORION-9, ORION-10 or ORION-11 trials.

PDF
Download
Preview image. A patient's guide to LEQVIO® (inclisiran) thumbnail.

A patient’s guide to LEQVIO®

PDF
Download

A patient’s guide to LEQVIO®

Please note that this material should only be shared with patients for whom the decision to prescribe LEQVIO® has already been made.

This downloadable PDF can be shared with your LEQVIO® patients to provide them with further information on their condition and useful information regarding taking LEQVIO®.

Please do not share this web page directly with patients. Instead, please provide them with a hardcopy of the 'Patient's guide to LEQVIO', or the patient information leaflet available on www.medicines.ie.

Please get in touch with us to speak to one of our Novartis representatives

Contact us

ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.

Reference

  1. LEQVIO® Summary of Product Characteristics.

IE11497577 | April 2026

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.